{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T05:01:28Z","timestamp":1780203688729,"version":"3.54.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["BYSYFY2021016"],"award-info":[{"award-number":["BYSYFY2021016"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009399","name":"Peking University Third Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020AAA0105203"],"award-info":[{"award-number":["2020AAA0105203"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104294"],"award-info":[{"award-number":["82104294"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178168","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T03:56:51Z","timestamp":1757995011000},"page":"178168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prognostic implications of antitumour efficacy and adverse events of EGFR-TKIs in non-small cell lung cancer: an ambispective cohort study"],"prefix":"10.1016","volume":"1006","author":[{"given":"Ling","family":"Yong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan'e","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhe","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3052-8291","authenticated-orcid":false,"given":"Lei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2225-3987","authenticated-orcid":false,"given":"Pingyao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7748-7285","authenticated-orcid":false,"given":"Enze","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2051-3134","authenticated-orcid":false,"given":"Qingyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-5156","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178168_bib1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/psp4.13003","article-title":"Model-based prediction of progression-free survival for combination therapies in oncology","volume":"12","author":"Baaz","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178168_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/1078-0432.CCR-22-2323","article-title":"Tumor dynamic model-based decision support for phase Ib\/II combination studies: a retrospective assessment based on resampling of the phase III study IMpower150","volume":"29","author":"Bruno","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178168_bib3","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178168_bib4","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/psp4.12841","article-title":"Tumor growth inhibition modeling to support the starting dose for dacomitinib","volume":"11","author":"Fostvedt","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178168_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12876-022-02542-0","article-title":"Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma","volume":"22","author":"Gu","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ejphar.2025.178168_bib6","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/psp.2013.18","article-title":"A time to event tutorial for pharmacometricians","volume":"2","author":"Holford","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178168_bib7","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2009.25.0654","article-title":"Basic concepts and methods for joint models of longitudinal and survival data","volume":"28","author":"Ibrahim","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178168_bib8","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(14)70461-9","article-title":"Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial","volume":"15","author":"J\u00e4nne","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2025.178168_bib9","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178168_bib10","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/cts.13300","article-title":"Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer","volume":"15","author":"Janssen","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejphar.2025.178168_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/cpt.3113","article-title":"Longitudinal circulating tumor DNA modeling to predict disease progression in first-line mutant epidermal growth factor receptor non-small cell lung cancer","volume":"115","author":"Johnson","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178168_bib12","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","article-title":"Automated covariate model building within NONMEM","volume":"15","author":"Jonsson","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejphar.2025.178168_bib13","article-title":"Regulating miRNAs expression by resveratrol: novel insights based on molecular mechanism and strategies for cancer therapy","volume":"17","author":"Keshavarzmotamed","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178168_bib14","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1158\/1078-0432.CCR-12-2934","article-title":"Overview: progression-free survival as an endpoint in clinical trials with solid tumors","volume":"19","author":"Korn","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178168_bib15","article-title":"Efficacy and safety of selective cyclin-dependent kinases 4\/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting","volume":"25","author":"Kova\u010c","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.ejphar.2025.178168_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/psp4.12629","article-title":"Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel","volume":"10","author":"Krishnan","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178168_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.11.002","article-title":"MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: current implications and future directions","volume":"42","author":"Leonetti","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejphar.2025.178168_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114022","article-title":"Progression-free survival estimates are shaped by specific censoring rules: implications for PFS as an endpoint in cancer randomized trials","volume":"202","author":"Lesan","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178168_bib19","first-page":"62","article-title":"Breaking boundaries: chronic diseases and the frontiers of immune microenvironments","volume":"1","author":"Li","year":"2025","journal-title":"Media Res."},{"key":"10.1016\/j.ejphar.2025.178168_bib20","article-title":"Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178168_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e20551","article-title":"Associations of early adverse events with clinical outcomes in patients with NSCLC treated with EGFR tyrosine kinase inhibitors","volume":"42","author":"Lin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178168_bib22","article-title":"Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2025.178168_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cpan.2024.12.002","article-title":"Advances in drug discovery based on network pharmacology and omics technology","volume":"21","author":"Liu","year":"2024","journal-title":"Curr. Pharmaceut. Anal."},{"key":"10.1016\/j.ejphar.2025.178168_bib24","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178168_bib25","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178168_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejphar.2025.178168_bib27","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1378\/chest.117.6.1568","article-title":"Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer","volume":"117","author":"Patz","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2025.178168_bib28","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.ejca.2015.07.005","article-title":"The role of censoring on progression free survival: oncologist discretion advised","volume":"51","author":"Prasad","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178168_bib29","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178168_bib30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.178168_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","article-title":"Safety and tolerability of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.178168_bib32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/psp4.13094","article-title":"Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: a case study from GEMSTONE-302","volume":"13","author":"Sheng","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178168_bib33","article-title":"20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight","volume":"1878","author":"Singh","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejphar.2025.178168_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178168_bib35","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1200\/JCO.2018.36.15_suppl.9578","article-title":"Time to treatment failure (TTF) as a potential clinical endpoint in real-world evidence (RWE) studies of melanoma","volume":"36","author":"Sridhara","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178168_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178168_bib38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/clpt.2009.64","article-title":"Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development","volume":"86","author":"Wang","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178168_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cpan.2024.12.001","article-title":"Emerging trends and hot topics in the application of multi-omics in drug discovery: a bibliometric and visualized study","volume":"21","author":"Wang","year":"2024","journal-title":"Curr. Pharmaceut. Anal."},{"key":"10.1016\/j.ejphar.2025.178168_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12916-022-02675-9","article-title":"Frailty and risk of microvascular complications in patients with type 2 diabetes: a population-based cohort study","volume":"20","author":"Wu","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.ejphar.2025.178168_bib41","article-title":"Roles of MicroRNA-21 in skin wound healing: a comprehensive review","volume":"13","author":"Xie","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178168_bib42","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/psp4.12835","article-title":"Longitudinal and time-to-event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma","volume":"11","author":"Yao","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178168_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41401-025-01573-z","article-title":"Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer","author":"Yong","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2025.178168_bib44","first-page":"10","article-title":"Optimized dynamic network biomarker deciphers a high-resolution heterogeneity within thyroid cancer molecular subtypes","volume":"1","author":"Zhang","year":"2025","journal-title":"Media Res."},{"key":"10.1016\/j.ejphar.2025.178168_bib45","first-page":"e152","article-title":"Efficacy and safety comparison of regorafenib and fruquintinib in metastatic colorectal Cancer-An observational cohort study in the real world","volume":"21","author":"Zhang","year":"2022","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ejphar.2025.178168_bib46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in Cox regression models","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann. Transl. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:39:16Z","timestamp":1780202356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"alternative-id":["S0014299925009227"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178168","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic implications of antitumour efficacy and adverse events of EGFR-TKIs in non-small cell lung cancer: an ambispective cohort study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178168"}}